Bookmarks
NICAM: Nilotinib treatment for c-KIT mutated advanced AMM
Population Size
Not reported
Years
2009
Associated BioSamples
Availability to be confirmed
Geographic coverage
United Kingdom
England
Lead time
Other
Summary
Collection of samples and data across the following diseases: Malignant melanoma of eye (disorder).
Documentation
Phase II single arm study evaluating the activity of nilotinib in rare c-KIT mutated acral and mucosal melanoma (AMM). Entry into the trial is a 2 step process. Patients presenting with AMM are first registered (Step 1) for screening including confirmation of c-KIT mutation status. Eligible patients who proceed to study entry (step 2) commence treatment with nilotinib 400 mgs twice daily for as long as they continue to benefit from treatment.
Dataset type
Health and disease
Dataset sub-type
Not applicable
Keywords
Provenance
Image contrast
Not stated
Biological sample availability
Availability to be confirmed
Details
Publishing frequency
Other
Version
1.0.0
Modified
08/10/2024
Citation Requirements
In Progress
Coverage
Start date
01/01/2009
Time lag
Variable
Geographic coverage
United Kingdom, England
Accessibility
Language
en
Controlled vocabulary
LOCAL
Format
In Progress
Data Access Request
Dataset pipeline status
Not available
Access rights
Please contact the publisher using Contact Point details provided.
Time to dataset access
Other
Access request cost
Not specified
Access method category
Varies based on project
Data Controller
The Institute of Cancer Research